Tags

Type your tag names separated by a space and hit enter

Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100.
J Clin Invest. 2000 Dec; 106(12):1501-10.JCI

Abstract

Apo-E-deficient apo-B100-only mice (APOE:(-/-)APOB:(100/100)) and LDL receptor-deficient apo-B100-only mice (LDLR:(-/-)APOB:(100/100)) have similar total plasma cholesterol levels, but nearly all of the plasma cholesterol in the former animals is packaged in VLDL particles, whereas, in the latter, plasma cholesterol is found in smaller LDL particles. We compared the apo-B100-containing lipoprotein populations in these mice to determine their relation to susceptibility to atherosclerosis. The median size of the apo-B100-containing lipoprotein particles in APOE:(-/-)APOB:(100/100) plasma was 53.4 nm versus only 22.1 nm in LDLR:(-/-)APOB:(100/100) plasma. The plasma levels of apo-B100 were three- to fourfold higher in LDLR:(-/-)APOB:(100/100) mice than in APOE:(-/-)APOB:(100/100) mice. After 40 weeks on a chow diet, the LDLR:(-/-)APOB:(100/100) mice had more extensive atherosclerotic lesions than APOE:(-/-)APOB:(100/100) mice. The aortic DNA synthesis rate and the aortic free and esterified cholesterol contents were also higher in the LDLR:(-/-)APOB:(100/100) mice. These findings challenge the notion that all non-HDL lipoproteins are equally atherogenic and suggest that at a given cholesterol level, large numbers of small apo-B100-containing lipoproteins are more atherogenic than lower numbers of large apo-B100-containing lipoproteins.

Authors+Show Affiliations

Gladstone Institute of Cardiovascular Disease, Cardiovascular Research Institute, University of California, San Francisco, California, USA. mveniant@amgen.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

11120757

Citation

Véniant, M M., et al. "Defining the Atherogenicity of Large and Small Lipoproteins Containing Apolipoprotein B100." The Journal of Clinical Investigation, vol. 106, no. 12, 2000, pp. 1501-10.
Véniant MM, Sullivan MA, Kim SK, et al. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. J Clin Invest. 2000;106(12):1501-10.
Véniant, M. M., Sullivan, M. A., Kim, S. K., Ambroziak, P., Chu, A., Wilson, M. D., Hellerstein, M. K., Rudel, L. L., Walzem, R. L., & Young, S. G. (2000). Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. The Journal of Clinical Investigation, 106(12), 1501-10.
Véniant MM, et al. Defining the Atherogenicity of Large and Small Lipoproteins Containing Apolipoprotein B100. J Clin Invest. 2000;106(12):1501-10. PubMed PMID: 11120757.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. AU - Véniant,M M, AU - Sullivan,M A, AU - Kim,S K, AU - Ambroziak,P, AU - Chu,A, AU - Wilson,M D, AU - Hellerstein,M K, AU - Rudel,L L, AU - Walzem,R L, AU - Young,S G, PY - 2000/12/20/pubmed PY - 2001/2/28/medline PY - 2000/12/20/entrez SP - 1501 EP - 10 JF - The Journal of clinical investigation JO - J Clin Invest VL - 106 IS - 12 N2 - Apo-E-deficient apo-B100-only mice (APOE:(-/-)APOB:(100/100)) and LDL receptor-deficient apo-B100-only mice (LDLR:(-/-)APOB:(100/100)) have similar total plasma cholesterol levels, but nearly all of the plasma cholesterol in the former animals is packaged in VLDL particles, whereas, in the latter, plasma cholesterol is found in smaller LDL particles. We compared the apo-B100-containing lipoprotein populations in these mice to determine their relation to susceptibility to atherosclerosis. The median size of the apo-B100-containing lipoprotein particles in APOE:(-/-)APOB:(100/100) plasma was 53.4 nm versus only 22.1 nm in LDLR:(-/-)APOB:(100/100) plasma. The plasma levels of apo-B100 were three- to fourfold higher in LDLR:(-/-)APOB:(100/100) mice than in APOE:(-/-)APOB:(100/100) mice. After 40 weeks on a chow diet, the LDLR:(-/-)APOB:(100/100) mice had more extensive atherosclerotic lesions than APOE:(-/-)APOB:(100/100) mice. The aortic DNA synthesis rate and the aortic free and esterified cholesterol contents were also higher in the LDLR:(-/-)APOB:(100/100) mice. These findings challenge the notion that all non-HDL lipoproteins are equally atherogenic and suggest that at a given cholesterol level, large numbers of small apo-B100-containing lipoproteins are more atherogenic than lower numbers of large apo-B100-containing lipoproteins. SN - 0021-9738 UR - https://www.unboundmedicine.com/medline/citation/11120757/Defining_the_atherogenicity_of_large_and_small_lipoproteins_containing_apolipoprotein_B100_ L2 - https://doi.org/10.1172/JCI10695 DB - PRIME DP - Unbound Medicine ER -